procabio a european initiative to develop tailored treatment of prostate cancer by biomarkers
DESCRIPTION
PROCABIO A European initiative to develop tailored treatment of prostate cancer by biomarkers. Objectives PROCABIO (Tailored treatment of pro state ca ncer by bio markers). Integration biomarkers in updated and improved model for indolent prostate cancer - PowerPoint PPT PresentationTRANSCRIPT
PROCABIO
A European initiative to develop
tailored treatment of prostate cancer
by biomarkers
Objectives PROCABIO(Tailored treatment of prostate cancer by biomarkers)
Integration biomarkers in updated and improved model for indolent prostate cancer
Integration biomarkers in development of guidelines for efficient strategies for active surveillance
Delivery validated biomarker tools that are easily applicable for high throughput use in clinical and screening settings
Establishment overall acceptance of active surveillance as a treatment modality for indolent prostate cancer
For more information, contact [email protected]
11 clinical & academic partners 5 commercial partners
Erasmus MC (NL) Abacus Diagnostica (FIN)
Institute of Cancer Research (UK) Beckman-Coulter (FR)
L’Hôpital Saint-Louis (FR) Epigenomics (GE)
Lund University (SE) Gen-Probe Incorporated (USA)
Milan National Cancer Institute (I) Orion Diagnostica Oy (FIN)
RUNMC (NL)
University of Helsinki (FIN) 2 advisory partners
University of Münster (GE) EORTC (BE)
University of Sheffield (UK) Europa Uomo (BE)
University of Tampere (FIN)
University of Turku (FIN)
PROCABIO consortium (18 partners)
For more information, contact [email protected]
PROCABIO plan for 3 years
For more information, contact [email protected]
Active surveillance trial in 8 centers according to PRIAS protocol with 3 years follow-up
Central biorepository of blood and urine
Validation in blood, urine or tissue of proteomic and genomic biomarkers discriminating indolent
and progressive PCa
Informing stakeholders on progress and outcome active surveillance study & biomarker
implementation
Biomarker implementation in treatment policies
Guidelines on active surveillance
PCa patients involvement (Europa Uomo)
Archival Biomaterials (via P-Mark, ERSPC, ProtecT)
Prospective Biomaterials (via PRIAS-study)
Genomic, proteomic,molecular pathology
Biomarkers
Marker based guidelines for PCa patients (EORTC, EAU)
FinlandFranceGermanyNetherlandsSwedenUK
Clinical Centresimplementation targeted treatment
BelgiumItalyLithuania
Marker industriesAbacusBeckman CoulterEpigenomicsGen-ProbeOrion
Academic Research Malmö Nijmegen Munster Rotterdam Sheffield Turku Helsinki
Europe as a scaffold to integrate research for prostate cancer patients
PROCABIO contact details
PROCABIO coordinator PROCABIO project manager
Prof. dr. Chris Bangma Dr. Ellen Schenk-Braat
Erasmus MC Erasmus MC
Department of Urology Department of Urology
Room H1096 JNI, room Be362
T. +31-10-7033607 T. +31-10-7043674
F. +31-10-7035838 F. +31-10-7044661
Erasmus MC Department of Urology
PI Prof. dr. Chris Bangma
50 patients
University Hospital Malmö Department of Urology
PI Prof. dr. Anders Bjartell
25 patients
Institute of Cancer Research, London
PI Dr. Chris Parker
100 patients
Tampere University Hospital Department of Urology
PI Prof. dr. Teuvo Tammela
80-100 patients
Milan National Cancer Institute
PI Prof. dr. Riccardo Valdagni
40 patients
EAU Best paper 2007 by a resident
Integrating Europe for Prostate Cancer
2007
Prostate Cancer
Risk Calculator
Patient organisations
…early detection…
Biomarker
research
2002
Health care professionals
2007
Prostate Cancer International
study of Active Surveillance
2006
PROCABIOProstate Cancer Biomarker research in clinical setting of
Active Surveillance 2008
2008